| answer text |
<p>The Department is doing everything appropriate to prepare for leaving the European
Union. We want to reassure patients that our plans should ensure the uninterrupted
supply of medicines and medical products, including insulin, once we have left the
EU.</p><p>The Department, as part of our EU exit preparations, is implementing a multi-layered
approach to mitigate potential disruption to supply, which consists of stockpiling
where possible, securing freight capacity, changing or clarifying regulatory requirements,
procuring additional warehousing, working closely with industry to improve trader
readiness and putting in place the National Supply Disruption Response to manage potential
shortages.</p><p>As an example of the preparations being taken by industry to prepare
for EU exit, all three suppliers of insulin have publicly stated that they have significantly
increased their United Kingdom stockpiles, and have met the Government’s request that
they hold at least six weeks’ worth of extra stock in addition to their usual operational
stocks.</p>
|
|
